Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca commits to cooperting with China fraud probe after billions wiped from valuation
04:13am, Wednesday, 06'th Nov 2024
AstraZeneca PLC (LSE:AZN) has committed to working with Chinese authorities after reports several executives were implicated in a fraud case wiped billions off its valuation on Tuesday. Financial me
AstraZeneca Shares Slide As Execs in China Face Fraud Investigation
05:51pm, Tuesday, 05'th Nov 2024
AstraZeneca (AZN) shares dropped Tuesday after a report that dozens of the company's senior executives in China potentially have been implicated in an insurance fraud case, according to a report from
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
03:09pm, Tuesday, 05'th Nov 2024
Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.
AstraZeneca sheds £15 billion of market cap as weight-loss-pill data underwhelms investors
12:26pm, Tuesday, 05'th Nov 2024
AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill.
AstraZeneca shares fall on report of potential China probe fallout
11:09am, Tuesday, 05'th Nov 2024
AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior executives at its China unit could be implicated in the largest insurance fr
AstraZeneca sheds £15bn in value as weight loss drug data ‘underwhelming'
10:34am, Tuesday, 05'th Nov 2024
AstraZeneca PLC (LSE:AZN) shed £15 billion in value on Tuesday as shares plummeted following the release of early data on its weight loss drug portfolio. Shares fell by 8.6% on Tuesday, taking the ph
AstraZeneca says experimental obesity pill safe and tolerable in early-stage trial
10:05am, Monday, 04'th Nov 2024
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with the GLP-1 drug class.
3 Magnificent Stocks Under $100 to Buy in November
06:41am, Sunday, 03'rd Nov 2024
The price could be right for these stocks.
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
07:16pm, Friday, 01'st Nov 2024
In the most recent trading session, Astrazeneca (AZN) closed at $71.42, indicating a +0.38% shift from the previous trading day.
3 Rock-Solid Dividend Stocks You Can Buy and Hold Forever
07:00am, Thursday, 31'st Oct 2024
In a frothy market starved for value, these three dividend stocks combine reasonable valuations with the proven ability to disrupt themselves.
AstraZeneca hit again as Chinese president investigated by police
05:29am, Thursday, 31'st Oct 2024
AstraZeneca PLC (LSE:AZN) has confirmed that the president of its China division has been placed under investigation by local police as part of an anti-corruption drive. Leon Wang, who forms part of
AstraZeneca says its China operations president under investigation
09:24am, Wednesday, 30'th Oct 2024
AstraZeneca said on Wednesday the company's China President Leon Wang is currently under investigation and is cooperating with Chinese authorities.
Astrazeneca (AZN) Declines More Than Market: Some Information for Investors
07:20pm, Friday, 25'th Oct 2024
Astrazeneca (AZN) closed the most recent trading day at $75.05, moving -1.12% from the previous trading session.
AstraZeneca positioned for success in key breast cancer drug trials, says leading US investment bank
09:54am, Friday, 25'th Oct 2024
JP Morgan analysts see AstraZeneca PLC (LSE:AZN) in a strong position to dominate the market for a new breast cancer treatment if upcoming clinical trial results are positive. Its drug candidate, cami
Monopar Therapeutics Inc. MNPR stock is skyrocketing on Thursday.
